248282-01-1
248282-01-1 結構式
基本信息
N,5-二乙基-4-羥基-1-甲基-2-氧代-N-苯基-1,2-二氫喹啉-3-甲酰胺
ABR 25757
ABR-25757
ABR?215757
Paquinimod
ABR?215757
ABR 215757
ABR215757
PAQUINIMOD.
ABR 25757
ABR-25757
ABR25757
PAQUINIMOD
248282-01-1
N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
3-Quinolinecarboxamide, N,5-diethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-N-phenyl-
物理化學性質
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/02/08 | HY-100442 | 帕奎莫德 Paquinimod | 248282-01-1 | 5 mg | 930元 |
| 2025/02/08 | HY-100442 | 帕奎莫德 Paquinimod | 248282-01-1 | 10mM * 1mLin DMSO | 1020元 |
| 2025/02/08 | HY-100442 | 帕奎莫德 Paquinimod | 248282-01-1 | 10mg | 1500元 |
常見問題列表
S100A9
S100A9 is a calcium-binding protein of the S100 family. Paquinimod is an immunomodulatory compound preventing S100A9 binding to TLR-4. Prophylactic treatment with S100A9 inhibitor Paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Paquinimod is a potent inhibitor of insulitis and diabetes development in the NOD mouse. To assess the preventive efficacy of Paquinimod on diabetes development in female NOD mice, groups of mice are treated with daily doses of 0.04, 0.2, 1, and 5 mg/kg/day of Paquinimod from week 10 of age until week 20 of age. Glycosuria is analyzed on a weekly basis from 10 weeks of age until the endpoint of the experiment at 40 weeks of age. There is a clear dose-dependent reduction in diabetes development in the Paquinimod-treated mice.